Researchers are reporting a potential breakthrough in cancer immunotherapy, addressing a critical challenge that has limited its effectiveness against solid tumors. A team at UCLA has developed a method to “supercharge” immune cells by providing them with a unique fuel source that cancer cells can’t easily access, significantly improving their ability to survive and attack tumors in preclinical studies. The findings, published in the journal Cell, offer a promising strategy to overcome a major obstacle in cancer treatment.
The Fuel Shortage Problem in Immunotherapy
Immunotherapy, particularly CAR-T cell therapy, has shown remarkable success in treating blood cancers. However, its application to solid tumors – such as those found in the lungs, breasts, and colon – has been hampered by the tumor microenvironment. Solid tumors create a metabolically challenging landscape for immune cells. As , researchers explained, tumor cells aggressively consume glucose, a key nutrient, from their surroundings. This leaves T cells, the immune cells responsible for attacking cancer, starved of energy and unable to effectively kill cancer cells.
“A problem with solid tumors is that the immune system tries to fight the cancer, but the tumor cells deplete the key nutrient glucose from their environment,” said Dr. Manish Butte, UCLA’s E. Richard Stiehm Professor of Pediatric Allergy, Immunology and Rheumatology and a member of the UCLA Health Jonsson Comprehensive Cancer Center. “This leaves the T cells that show up to attack with not enough glucose to make cytokines and kill. The balance between tumor cells eating the glucose and the T cells not having enough glucose is a key reason why tumors spread and elude immune attack.”
Cellobiose: A Protected Fuel Source
To circumvent this metabolic roadblock, the UCLA team focused on finding a way to feed T cells glucose without simultaneously fueling the tumor’s growth. Their solution lies in cellobiose, a naturally occurring sugar found in plant fiber (cellulose). Cellobiose is considered non-toxic and is generally recognized as safe by the U.S. Food and Drug Administration, routinely appearing in foods like infant formula, drinks, candies, and icings.
Crucially, human cells and tumors lack the necessary enzymes to break down cellobiose. This means that when T cells are provided with cellobiose, they can metabolize it for energy, while the tumor cells are unable to utilize it, effectively creating a selective advantage for the immune cells. The researchers developed a method to deliver cellobiose specifically to the T cells, ensuring that the tumor doesn’t benefit from the added sugar.
Preclinical Results and Future Directions
In preclinical studies, the approach demonstrated a significant improvement in the ability of T cells to survive and attack solid tumors. The researchers observed that T cells fueled with cellobiose were more resilient and maintained their anti-cancer activity for a longer duration. This suggests that providing a protected sugar source can overcome the metabolic exhaustion that often limits the effectiveness of immunotherapy in solid tumors.
The research builds upon a growing understanding of the importance of metabolic factors in cancer treatment. Other studies have highlighted the role of glucose metabolism in both cancer cell growth and immune function. A 2020 article published in Cancers journal explored how manipulating glucose availability could be a valuable tool to limit cancer cell growth and enhance the immune response. This UCLA study takes that concept a step further by providing a targeted fuel source for immune cells, avoiding the pitfalls of simply increasing glucose levels in the tumor microenvironment.
Implications for Cancer Treatment
While these findings are promising, it’s important to note that the research is currently in its early stages. The studies have been conducted in preclinical models, and further research is needed to determine the safety and efficacy of this approach in humans. Clinical trials will be necessary to evaluate whether cellobiose-fueled T cells can effectively treat solid tumors in patients.
However, the UCLA team’s work represents a significant step forward in addressing a major challenge in cancer immunotherapy. By overcoming the metabolic constraints that limit T cell function, this strategy could potentially unlock the full potential of immunotherapy for a wider range of cancers. If successful, this approach could offer a new avenue for treating aggressive solid tumors that have proven resistant to conventional therapies.
The researchers are optimistic that this strategy could be combined with existing immunotherapies, such as CAR-T cell therapy, to further enhance their effectiveness. The ability to provide a sustained and protected fuel source for T cells could be particularly beneficial in patients with advanced or metastatic cancer, where the tumor microenvironment is often highly immunosuppressive.
